Drug Trial Radar · NCT07246291
Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Nov 11, 2025
Primary completion
Apr 14, 2026
Study completion Apr 14, 2026
Sponsor
- Lead sponsor
- Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, double-Blind, parallel-controlled, single-dose pharmacokinetic, safety, and immunogenicity comparative study of EnliTuo® before and after technology change in healthy male volunteers.
Conditions
- Healthy Adult Male
Interventions
New technology EnlituoBiological
250 mg/m\^2, single intravenous drip
Approved technology EnlituoBiological
250 mg/m\^2, single intravenous drip
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-∞Time frame: From enrollment to the end of treatment at 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.